| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 2229.4 | 2290.0 | 1900.7 |
| Other income | 19.9 | 23.7 | 12.0 |
| Total income | 2249.3 | 2313.7 | 1912.7 |
| Profit before exceptional items & tax | 86.4 | 189.7 | 154.4 |
| Exceptional items | 0.0 | 13.7 | 0.0 |
| Profit before tax | 86.4 | 176.0 | 154.4 |
| Net profit | 56.4 | 119.3 | 102.5 |
| Operating margin | 3.8% | 7.6% | 8.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -45.00% |
|---|---|
| Net profit, quarter on quarter | -52.70% |
| Revenue, year on year | +17.30% |
| Operating profit, year on year | -53.30% |
| Operating profit, quarter on quarter | -59.90% |
BSE results filing, NSE: JUBLPHARMA. Figures extracted from the filing.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹1,071.95
- Market cap
- ₹17,074 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 48.5×Sector 50.4×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Business Update
Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.
Jubilant Pharmova Earnings Call: Key Takeaways
Jubilant Pharmova Q4FY26 revenue grew 19% YoY to ₹2,290 Cr. FY26 revenue reached ₹8,280 Cr (up 14%) driven by CDMO Sterile Injectables and Radiopharma growth.
Jubilant Pharmova Q4 FY26 Results: Net Profit ₹119.3 Cr, Down 21.2% YoY
Jubilant Pharmova Ltd reported revenue from operations of ₹2,290 Cr (+18.7% YoY) and net profit of ₹119.3 Cr (-21.2% YoY) for Q4 FY26.
- Key figure
- Net profit ₹119.3 Cr · -21.2% YoY